Bladder cancer cells on a pink background

ESMO Congress 2025

Congress coverage by Medthority

Last updated: 28th Nov 2025

Published: 23rd Oct 2025

Get closer to the practice-changing conversations happening at this year’s European Society for Medical Oncology (ESMO) Congress with our selection of key highlights. Find the insights you need to know, from innovative immune strategies for advanced non–small-cell lung cancer (NSCLC) to expert opinion on the latest trial data for metastatic prostate cancer (mPC).

ESMO 2025: Advances in bladder and prostate cancer management

Catch up with new research targeting HRR mutations in mPC, plus key trials of treatments for NMIBC, including mixed results for upfront combination therapy in BCG-naive disease.

Developed independently by EPG Health with an educational grant from Pfizer.

MIBC: Trial update

“This is a remarkably important study.” Neal Shore discusses the efficacy and safety findings of the KEYNOTE-905 trial in muscle-invasive bladder cancer.

WATCH NOW

Antibody–drug conjugate in blue with four drug compounds on a blurred background.

ESMO 2025: ADCs for bladder cancer

View the latest updates on ADCs for bladder cancer, presented by Enrique Grande Pulido and Bernadett Szabados at ESMO 2025.

VIEW NOW

Complete the form below to receive our regular round-up of the latest clinical news and medical education resources on Medthority, straight to your inbox.

* = required information

Name

Email address

Specialty

By providing your email address, you are opting in to receive our monthly newsletter.

Opt-in: By selecting this box, I consent to receiving marketing communications and information about Medthority's resources by email.

By submitting this form you agree to our Terms of Use and Privacy Policy. You can withdraw your consent at any time by clicking the ‘unsubscribe’ link found at the bottom of every email.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event